Iovance Biotherapeutics I... (IOVA)
NASDAQ: IOVA
· Real-Time Price · USD
2.54
0.09 (3.67%)
At close: Aug 15, 2025, 3:59 PM
2.57
0.98%
After-hours: Aug 15, 2025, 04:10 PM EDT
Iovance Biotherapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 241.52M | 212.68M | 164.07M | 90.86M | 32.77M | 1.9M | 1.19M | 707K | 238K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 191.77M | 166.47M | 124M | 92.53M | 57.05M | 27.73M | 26.17M | 17.79M | 13.45M | 16.61M | 15.89M | 14.77M | 21.02M | 16.3M | 13.98M | 9.4M | 3.15M | 2.66M |
Gross Profit | 49.75M | 46.2M | 40.07M | -1.67M | -24.28M | -25.83M | -24.98M | -17.09M | -13.22M | -16.61M | -15.89M | -14.77M | -21.02M | -16.3M | -13.98M | -9.4M | -3.15M | -2.66M |
Operating Income | -410.64M | -398.78M | -395.28M | -429.96M | -459.25M | -467.43M | -460.56M | -446.34M | -428.37M | -418.02M | -398.88M | -391.31M | -377.15M | -358.85M | -342.7M | -311.77M | -284.5M | -266.7M |
Interest Income | 20.9M | 20.16M | 20.27M | 13.82M | 13.17M | 12.89M | 13.04M | 11.64M | 9.06M | 6.37M | 2.98M | 1.4M | 746K | 436K | 451K | 453K | 728K | 1.26M |
Pretax Income | -389.73M | -378.62M | -375M | -416.14M | -446.08M | -454.53M | -447.52M | -434.7M | -419.31M | -411.66M | -395.89M | -389.9M | -376.41M | -358.41M | -342.25M | -311.32M | -283.77M | -265.44M |
Net Income | -389.92M | -375.36M | -372.18M | -410M | -440.22M | -449.64M | -440.55M | -426.06M | -411.92M | -404.35M | -391.97M | -389.41M | -375.92M | -358.3M | -342.25M | -311.32M | -283.77M | -265.44M |
Selling & General & Admin | 163.68M | 160.17M | 142.37M | 120.05M | 107.46M | 95.2M | 97.2M | 103.48M | 104.41M | 108.81M | 104.1M | 101.48M | 94.48M | 87.46M | 83.66M | 75.9M | 70.93M | 65.97M |
Research & Development | 296.71M | 279.43M | 282.34M | 297.58M | 316.86M | 341.13M | 344.08M | 337.18M | 322.16M | 309.21M | 294.78M | 289.82M | 282.68M | 271.39M | 259.04M | 235.87M | 213.57M | 200.72M |
Other Expenses | -1K | 5.38M | 10.65M | 10.65M | 10.65M | 5.27M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 460.39M | 444.98M | 435.35M | 428.28M | 434.98M | 441.6M | 441.28M | 440.66M | 426.56M | 418.02M | 398.88M | 391.31M | 377.15M | 358.85M | 342.7M | 311.77M | 284.5M | 266.7M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | 17.14M | 17.14M | 1.64M | -11.27M | -11.27M | -11.27M | -29.13M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 652.16M | 611.46M | 559.35M | 520.82M | 492.02M | 469.33M | 461.75M | 447.05M | 428.61M | 418.02M | 398.88M | 391.31M | 377.15M | 358.85M | 342.7M | 311.77M | 284.5M | 266.7M |
Income Tax Expense | 188K | -3.26M | -2.83M | -6.14M | -5.87M | -4.89M | -6.96M | -8.64M | -7.4M | -7.3M | -3.92M | -491K | -491K | -228K | -122K | -122K | -429K | -307K |
Shares Outstanding (Basic) | 334.51M | 322.87M | 304.89M | 303.27M | 284.82M | 266.22M | 255.95M | 245.82M | 224.48M | 213.69M | 164.76M | 157.82M | 157.27M | 157.11M | 156.92M | 155.51M | 153.75M | 147.37M |
Shares Outstanding (Diluted) | 334.51M | 322.87M | 304.89M | 303.27M | 284.82M | 266.22M | 255.95M | 245.82M | 224.48M | 213.69M | 164.76M | 157.82M | 157.27M | 157.11M | 156.92M | 155.51M | 153.75M | 147.37M |
EPS (Basic) | -1.23 | -1.24 | -1.3 | -1.49 | -1.67 | -1.8 | -1.88 | -2.05 | -2.22 | -2.38 | -2.46 | -2.47 | -2.39 | -2.29 | -2.22 | -2.06 | -1.91 | -1.85 |
EPS (Diluted) | -1.23 | -1.24 | -1.3 | -1.49 | -1.67 | -1.8 | -1.88 | -2.05 | -2.22 | -2.38 | -2.46 | -2.47 | -2.39 | -2.29 | -2.22 | -2.06 | -1.91 | -1.85 |
EBITDA | -361.58M | -350.79M | -351.67M | -388.33M | -418.89M | -430.09M | -427.43M | -417.22M | -403.93M | -396.17M | -377.74M | -363.67M | -350.75M | -334.91M | -320.97M | -301.94M | -278.32M | -263.04M |
EBIT | -407.42M | -395.56M | -395.28M | -426.84M | -452.78M | -457.87M | -451M | -439.9M | -425.29M | -418.02M | -398.88M | -391.17M | -376.9M | -358.52M | -342.25M | -311.46M | -284.3M | -266.58M |
Depreciation & Amortization | 45.84M | 44.76M | 43.61M | 41.63M | 37.41M | 31.41M | 27.2M | 23.2M | 21.47M | 21.81M | 21.09M | 27.6M | 26.36M | 23.93M | 19.33M | 7.43M | 3.78M | 1.26M |